Lynparza (olaparib) — Medica
Pancreatic cancer – maintenance therapy
Initial criteria
- age ≥ 18 years
- germline BRCA mutation-positive metastatic disease
- disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
Approval duration
1 year